新浪登录
腾讯登录Cancer Genetics获批拓展肿瘤检测任务
| 导读 | 肿瘤诊断公司Cancer Genetics今天宣布其通过美国CLIA标准认证、CAP认证的实验室已经获得加州临床实验室许可。 |
肿瘤诊断公司Cancer Genetics今天宣布其通过美国CLIA（临床实验室改进修正案）标准认证、CAP认证（CAP认证，美国病理家协会举办的一种国际论证，自1962年起在美国普遍采用执行，1994年起被世界各国公认为最适合医疗检验室使用的国际级实验室标准，通过CAP认证的检验室代表其检验室品质达到世界顶尖水准，并获得国际间各相关机构认同）的实验室已经获得加州临床实验室许可，这将使该公司拥有加州肿瘤样本检测服务市场。
这家位于新泽西州的公司在一项声明中表示：“该公司确信其非霍奇金淋巴瘤(NHL)和白血病的专业化测量与评估服务将会使加州人民十分受益。”数据显示，全加州每年约新增6800例确诊NHL病例，4300例白血病确诊病例。
Cancer Genetics公司的 CEO Panna Sharma在一项声明中表示：“获得在加州提供肿瘤综合测试服务的批准将推动该公司开辟美国最大的肿瘤临床诊断市场，将帮助加速Cancer Genetics公司各种核心技术的商业化进程。”
Cancer Genetics公司在2014年5月获得了CLIA认证与纽约州的淋巴瘤检测服务许可，在2013年2月获得该州白血病测试服务许可。（转化医学网360zhyx.com）
The Rutherford, NJ-based firm said in a statement that it believes its proprietary tests for non-Hodgkin's lymphoma (NHL) and leukemia will be of particular benefit to the state, where more than 6,800 new patients are diagnosed with NHL, and 4,300 patients are diagnosed with leukemia each year.
"Approval to provide our comprehensive oncology tests and services throughout California opens up the single largest US oncology diagnostics market to CGI, and will help accelerate our commercial growth," Cancer Genetics CEO Panna Sharma said in a statement.
Cancer Genetics received CLIA and New York State approvals in May 2014 to offer its lymphoma tests and got the same approvals for its leukemia tests in February 2013.
这家位于新泽西州的公司在一项声明中表示：“该公司确信其非霍奇金淋巴瘤(NHL)和白血病的专业化测量与评估服务将会使加州人民十分受益。”数据显示，全加州每年约新增6800例确诊NHL病例，4300例白血病确诊病例。
Cancer Genetics公司的 CEO Panna Sharma在一项声明中表示：“获得在加州提供肿瘤综合测试服务的批准将推动该公司开辟美国最大的肿瘤临床诊断市场，将帮助加速Cancer Genetics公司各种核心技术的商业化进程。”
Cancer Genetics公司在2014年5月获得了CLIA认证与纽约州的淋巴瘤检测服务许可，在2013年2月获得该州白血病测试服务许可。（转化医学网360zhyx.com）
以上为转化医学网原创翻译整理，谢绝转载。如需转载，请联系 info@360zhyx.com 。
转化医学网推荐的新闻阅读：
Oncology diagnostics firm Cancer Genetics today announced that its CLIA-certified, CAP-accredited laboratory has received the California Clinical Laboratory License, which will allow the company to perform its oncology testing services on patient samples from the state of California.The Rutherford, NJ-based firm said in a statement that it believes its proprietary tests for non-Hodgkin's lymphoma (NHL) and leukemia will be of particular benefit to the state, where more than 6,800 new patients are diagnosed with NHL, and 4,300 patients are diagnosed with leukemia each year.
"Approval to provide our comprehensive oncology tests and services throughout California opens up the single largest US oncology diagnostics market to CGI, and will help accelerate our commercial growth," Cancer Genetics CEO Panna Sharma said in a statement.
Cancer Genetics received CLIA and New York State approvals in May 2014 to offer its lymphoma tests and got the same approvals for its leukemia tests in February 2013.
还没有人评论，赶快抢个沙发